摘要 : This study compared the oncologic outcomes of treatment with oral adjuvant chemotherapy regimens, UFT/LV or capecitabine. Retrospectively, 258 patients were reviewed. 3-year RFS and OS were not significantly difference. The outcom... 展开 This study compared the oncologic outcomes of treatment with oral adjuvant chemotherapy regimens, UFT/LV or capecitabine. Retrospectively, 258 patients were reviewed. 3-year RFS and OS were not significantly difference. The outcomes also did not differ regardless of whether patients completed the scheduled total treatment dose. Treatment decisions can thus focus on other issues such as cost, convenience, and adverse effects. 收起